Stay updated with breaking news from Pharma Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Notice of 2023 Annual General Meeting of Shareholders To Be Held on December 7, 2023 at 10 a.m. EST NOTICE IS HEREBY GIVEN THAT the annual general meeting of...
Ruben A. Mesa, MD, FACP, discusses the results of the SIMPLIFY-1 and MOMENTUM trials and how the data led to the approval of momelotinib to treat intermediate or high-risk myelofibrosis in adult patients with anemia.
TORONTO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- On September 5th 2023, RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or ...
Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythaemia), in
TORONTO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the "Company" or "RAMM") (CSE:RAMM), announces that it intends to complete a non-brokered private